http://orcid.org/0000-0002-5405-2215
Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Cisio De Oliveira Brandao, Sandra Lewis, Darcie Sandschafer & Jeffrey Crawford. (2023) Two decades of pegfilgrastim: what have we learned? Where do we go from here?. Current Medical Research and Opinion 39:5, pages 707-718.
Read now
Read now
Kim Campbell, Nidhi Chadha, Seema Dimri, Weijia Wang & Edward Li. (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Review of Hematology 15:7, pages 619-633.
Read now
Read now
Christel Fontaine, Nele Claes, Marie-Pascale Graas, Khalil Kargar Samani, Peter Vuylsteke & Christof Vulsteke. (2021) Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg. Acta Clinica Belgica 76:1, pages 10-15.
Read now
Read now
John Edelsberg, Derek Weycker, Mark Bensink, Charles Bowers & Gary H. Lyman. (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion 36:3, pages 483-495.
Read now
Read now
Articles from other publishers (8)
Philip Q. Ding, Brandt J. Newcomer & Winson Y. Cheung. (2022) Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada. Cancers 14:24, pages 6197.
Crossref
Crossref
Sophia Z. Humphreys, Robert B. Geller & Paul Walden. (2022) Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit. Oncology and Therapy 10:2, pages 351-361.
Crossref
Crossref
Reshma L. Mahtani, Rajesh Belani, Jeffrey Crawford, David Dale, Lucy DeCosta, Prasad L. Gawade, Chanh Huynh, Tatiana Lawrence, Sandra Lewis, William W. MacLaughlin, Mohit Narang & Robert Rifkin. (2022) A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. Supportive Care in Cancer 30:7, pages 6135-6144.
Crossref
Crossref
Torisson Gustav, Rosenqvist Mari, Melander Olle & Resman Fredrik. (2022) Hospitalisations with infectious disease diagnoses in somatic healthcare between 1998 and 2019: A nationwide, register-based study in Swedish adults. The Lancet Regional Health - Europe 16, pages 100343.
Crossref
Crossref
Yu Zhu, Daihong Guo, Xianghao Kong, Siyuan Liu & Chengxuan Yu. (2022) A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study. Pharmacology 107:1-2, pages 69-80.
Crossref
Crossref
Ahuva Averin, Amanda Silvia, Lois Lamerato, Kathryn Richert-Boe, Manpreet Kaur, Devi Sundaresan, Neel Shah, Mark Hatfield, Tatiana Lawrence, Gary H. Lyman & Derek Weycker. (2020) Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer 29:4, pages 2179-2186.
Crossref
Crossref
Jeffrey Crawford, Donald C. Moore, Vicki A. Morrison & David Dale. (2021) Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications 29, pages 100466.
Crossref
Crossref
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink & Gary H. Lyman. (2019) Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC Cancer 19:1.
Crossref
Crossref